Related Experiment Video

Updated: Jul 5, 2025

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K

Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: From Clinical Management to

Raffaella Mistrulli1, Armando Ferrera1, Melwyn Luis Muthukkattil1

  • 1Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy.

Journal of Clinical Medicine
|January 23, 2024
PubMed

Insights

Atrial fibrillation (AF) management in cardiomyopathy, including hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA), is crucial. Early rhythm control via catheter ablation may offer better outcomes than traditional medical therapy.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiomyopathy Research

Background:

  • Atrial fibrillation (AF) is a common arrhythmia in cardiomyopathy patients, affecting 27% with hypertrophic cardiomyopathy (HCM) and 40% with cardiac amyloidosis (CA).
  • AF presence accelerates functional decline, increases heart failure hospitalizations, and elevates thromboembolic risk.
  • Current medical management (beta-blockers, amiodarone) shows variable efficacy and high recurrence rates for AF in cardiomyopathy.

Purpose of the Study:

  • To review contemporary data on managing AF in patients with HCM and CA.
  • To evaluate the timing and outcomes of catheter ablation for AF in these specific patient populations.

Main Methods:

  • Literature review of current evidence on AF management in cardiomyopathy.
  • Analysis of data concerning catheter ablation timing and efficacy in HCM and CA patients.

Main Results:

  • Catheter ablation offers symptom burden reduction and complication mitigation for AF in cardiomyopathy, despite moderate recurrence rates.
  • Emerging evidence supports early rhythm control strategies for improved short- and long-term outcomes.

Conclusions:

  • Rethinking the timing of AF ablation in cardiomyopathy is essential for optimizing patient outcomes.
  • An early rhythm control approach, particularly with catheter ablation, shows promise for managing AF in HCM and CA patients.

Keywords:
atrial fibrillationcardiac amyloidosiscatheter ablatiohypertrophic cardiomyopathy

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.7K
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.8K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
961
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
922
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432